The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: C. M. Dintsios, I. Beinhauer
Format: Artigo
Langue:Inglês
Publié: BMC 2020-03-01
Collection:Health Economics Review
Sujets:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Accès en ligne:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires